Manufacturers of Metoclopramide & Tardive Dyskinesia

The medication metoclopramide, a treatment for various stomach and digestive disorders, was first developed in Europe in 1964 as an antipsychotic. Metoclopramide has been used in the treatment of gastroparesis (partial paralysis of the stomach) and symptoms associated with acid reflux disease (primarily heartburn). Since 1982 metoclopramide has been available as a generic drug and has been marketed under the trade names Maxolon and Reglan, among others.

A number of pharmaceutical manufactuers have produded metoclopramide, among them Schwarzs Pharma US, Teva Pharmaceuticals and URL Mututal Pharma. The pharmaceutical company profiles included here provide an overview of the company history and their involvement in the production of metoclopramide.

Metoclopramide has also been used to treat nausea and vomiting (including nausea associated with cancer treatments) and some women have been prescribed metoclopramide to stimulate lactation or to treat migraine headaches. Regardless of the reason for the prescription, those who are currently taking or have stopped taking the drug may be at risk of developing tardive dyskinesia (TD).

The Food and Drug Administration states that metoclopramide is "approved for the short-term (no longer than 3 months) treatment of gastrointestinal disorders," but warns that "frequent and long-term use of metoclopramide has been linked to tardive dyskinesia." Infants and children exposed to metoclopramide (whether directly or through breast milk) can also develop tardive dyskinesia.

In an effort to help patients and their families better understand tardive dyskinesia, Tardivedyskinesia.com is now offering a free informational packet. To receive your packet in the mail, please enter your information below.